Kwing-Ming Tsoi

NVIGEN, Inc. develops multifunctional and biodegradable nanoparticles. Its products include MagVigen, MaxVigen, MyQuVigen, and AuVigen. The company was founded by Aihua Fu and Guo Liang Yu and is headquartered in Campbell, CA.

The Chinese-American Biopharmaceutical Society is a non-profit organization for professionals in the biopharmaceutical industry. The non-profit company is based in San Francisco, CA, the birthplace of biotechnology and one of the largest biomedical hubs in the world. The company's membership consists of life science professionals from a broad range of experience levels, with a large percentage of members holding senior or executive positions in the industry. The society offers year-round sponsorship opportunities, including the highly anticipated 2023 annual BioPacific Conference, and leverages an extensive network of life sciences professionals.

The National Foundation for Cancer Research is a non-profit organization that provides funding to scientists for cancer research. The non-profit company is based in Bethesda, MD. The company's mission is to support life-saving discoveries for cancer patients.

University of the Pacific is a nationally ranked university with a long tradition of dedicated teaching, small class sizes, practical experience and vibrant residential life. The breathtaking main campus in Stockton, California is home to seven schools and colleges, with more than 80 majors and programs of study. Pacific also has the McGeorge School of Law in Sacramento and the Arthur A. Dugoni School of Dentistry in San Francisco. Total university enrollment is nearly 7,000, with 3,757 undergraduates in an average class size of 19 and a student/faculty ratio of 14:1. It is located in Stockton, California.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Apollomics, Inc. operates as a sciences oncology company. It is a biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company was founded by Sanjeev Gurunath Redkar and Guo-Liang Yu on May 21, 2015 and is headquartered in Foster City, CA.

Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA.

Applied StemCell, Inc. is a biotechnology company. Its products include stem cell research, genome editing products for cell line generation, primary cells from patient samples and isogenic cell lines. The company was founded by Ruhong Jiang, Ruby Yanru Chen-Tsai and Michael Cleary and is headquartered in Milpitas, CA.

QuanDx, Inc. provides molecular diagnostics. It specializes in the development and commercialization of novel diagnostic tools. The firm provides diagnostic and prognostic information for hematological and solid tumor cancers, as well as a number of infectious diseases. The company was founded by Matthew Lei and Guo-Liang Yu in 2012 and is headquartered in San Jose, CA.

Crown Bioscience, Inc. provides biomedical outsourcing solutions. It provides syngeneic and xenograft tumor models and custom model development and drug testing. The firm produces antibodies for therapeutic, diagnostic and theranostic applications. It also offers preclinical and drug development for anti-cancers therapeutics. The company was founded by Dr. Yiyou Chen, Dr. Yue Alexander Wu, Dr. William Pan and Dr. Faming Zhang in 2006 and is headquartered in Santa Clara, CA.

Alpine BioTherapeutics Corp. engages in the development of stem cell-based therapy to treat blindness. The company was founded by Jiagang Zhao and Ying Wu in 2017 and is headquartered in San Diego, CA.

Maijin Biomedical Technology (Shanghai) Co. Ltd. provides immunology-related therapeutic areas in China. The company is headquartered in Shanghai, China.

Zhejiang Innoforce Pharmaceuticals Co., Ltd. is a Chinese company that specializes in enabling the innovation and supply of RNA, plasmid DNA, cell and gene therapeutics. The private company is based in Hangzhou, China. The company has a world-class manufacturing and development hub that provides CDMO services.

Mendel Biotechnology, Inc. operates as a plant biotechnology company. It develops genetic and chemical solutions for a range of agricultural markets. The firm offers biofuel feedstocks, yield enhancement, flowering, drought tolerance, freezing tolerance, disease resistance, nutrient use efficiency, and cold germination products. The company was founded in 1997 and is headquartered in Newark, CA.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Waterstone Pharmaceuticals, Inc. engages in the provision of discovery, development, and commercialization of innovative drugs for the treatment of liver and gastrointestinal diseases. The company was founded by Faming Zhang in 2008 and is headquartered in Carmel, IN.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Jing Medicine Technology Shanghai Ltd. develops therapeutic monoclonal antibody and small molecule drugs. The private company is based in Shanghai, China.

MEDx Translational Medicine Co., Ltd. is a leading Chinese innovative company in companion diagnostics and precision medicine in China. The company is based in Suzhou, China. MEDx collaborates with hundreds of world-renowned pharmaceutical companies and has been rewarded with many certifications, including China CNAS, ISO17025, and US CAP ISO 13485, among others. The company was founded in 2013 as Qiagen Translational Medicine Co., Ltd. With comprehensive technology platforms, high-quality systems, and strong IVD R&D experience, MEDx offers integrated solutions from biomarker discovery to patient stratification for drug clinical trials, IVD/CDX R&D, and commercialization. The company was founded in 2013 by Ya Fei Zhang, who has been the CEO since then.

Kira Pharmaceuticals (Hong Kong) Ltd. manufactures pharmaceuticals. The private company is based in Hong Kong, Hong Kong.

Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang.

Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then.

Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.